Showing results (251-260 of 398) with videos related to
Sort By:
Pageof 40
The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology|December 29, 2018
XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin AmericaCarlos Arturo Areán Martínez, Fernando Lanas, Ghazi Radaideh, et al.Annals of Surgery|December 31, 2013
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trialAjay K Kakkar, Giancarlo Agnelli, William Fisher, et al.The Lancet. Haematology|January 15, 2016
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional studyWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.Applied Optics|February 3, 2016
Comparison of two methodologies for calibrating satellite instruments in the visible and near-infraredRobert A Barnes, Steven W Brown, Keith R Lykke, et al.Circulation|April 1, 1983
The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challengeR D Hull, C J Carter, R M Jay, et al.Thrombosis Research|March 3, 2019
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin AmericaReinhold Kreutz, Lorenzo G Mantovani, Sylvia Haas, et al.Journal of Thrombosis and Haemostasis : JTH|January 22, 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)B I Eriksson, A G G Turpie, M R Lassen, et al.Blood|February 1, 1982
The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosisA Zielinsky, J Hirsh, G Straumanis, et al.Annals of Internal Medicine|September 1, 1992
A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind studyA G Turpie, M Gent, R Côte, et al.Circulation|July 1, 1997
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)W Klein, A Buchwald, S E Hillis, et al.Pageof 40